Influence of immunosuppression on alloresponse, inflammation and contractile function of graft after intestinal transplantation.
In small bowel transplantation (SBTx), graft manipulation, ischemia/reperfusion injury and acute rejection initiate a severe cellular and molecular inflammatory response in the muscularis propria leading to impaired motility of the graft. This study examined and compared the effect of tacrolimus and sirolimus on inflammation in graft muscularis. After allogeneic orthotopic SBTx, recipient rats were treated with tacrolimus or sirolimus. Tacrolimus and sirolimus attenuated neutrophilic, macrophage and T-cell infiltration in graft muscularis, which was associated with reduced apoptotic cell death. Nonspecific inflammatory mediators (IL-6, MCP-1) and T-cell activation markers (IL-2, IFN-gamma) were highly upregulated in allogeneic control graft muscularis 24 h and 7 days after SBTx, and tacrolimus and sirolimus significantly suppressed upregulation of these mediators. In vitro organ bath method demonstrated a severe decrease in graft smooth muscle contractility in allogeneic control (22% of normal control). Correlating with attenuated upregulation of iNOS, tacrolimus and sirolimus treatment significantly improved contractility (64% and 72%, respectively). Although sirolimus reduced cellular and molecular inflammatory response more efficiently after 24 h, contrary tacrolimus prevented acute rejection more efficiently. In conclusion, tacrolimus and sirolimus attenuate cellular and molecular inflammatory response in graft muscularis and subsequent dysmotility of the graft after allogeneic SBTx.
Fujishiro
J
J
Department of Surgery, University of Bonn, Germany.
Pech
T C
TC
Finger
T F
TF
Praktinjo
M
M
Stoffels
B
B
Standop
J
J
Abu-Elmagd
K
K
Tuerler
A
A
Hirner
A
A
Kalff
J C
JC
Schaefer
N
N
D000818:Animals; D015703:Antigens, CD / Q000235:genetics; D017209:Apoptosis / Q000187:drug effects; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007249:Inflammation / Q000503:physiopathology* / Q000517:prevention & control; D007421:Intestine, Small / Q000502:physiology / Q000503:physiopathology / Q000637:transplantation*; D008297:Male; D009119:Muscle Contraction / Q000502:physiology*; D051381:Rats; D011914:Rats, Inbred BN; D011917:Rats, Inbred Lew; D020133:Reverse Transcriptase Polymerase Chain Reaction; D020123:Sirolimus / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000276:immunology; D016559:Tacrolimus / Q000627:therapeutic use; D014184:Transplantation, Homologous / Q000276:immunology; D014185:Transplantation, Isogeneic / Q000276:immunology
D015703:Antigens, CD; D007166:Immunosuppressive Agents; D020123:Sirolimus; D016559:Tacrolimus